Shen Jie, Moats Rex A, Pollack Harvey A, Robinson Michael R, Attar Mayssa
Allergan, An AbbVie Company, Irvine, CA, USA.
Moats Laboratory at the Saban Research Institute, Children's Hospital Los Angeles Research Imaging Core, Department of Radiology, Keck School of Medicine USC, Los Angeles, CA, USA.
Ophthalmol Ther. 2020 Dec;9(4):929-940. doi: 10.1007/s40123-020-00285-3. Epub 2020 Aug 1.
To qualitatively evaluate the ocular and periocular distribution of C-latanoprost following a single intracameral administration or repeated topical ocular administration in beagle dogs and cynomolgus monkeys.
In the dog study, three animals received an intracameral dose of C-latanoprost bilaterally and were euthanized at 1, 2, and 4 h post dose; three control animals received topical C-latanoprost bilaterally once daily for 5 days and were euthanized at 1, 4, and 24 h post final dose. Sagittal 40-µm sections of eyes with surrounding tissues were collected and processed for autoradiography. Methods in the monkey study were similar; two animals received a unilateral intracameral dose of C-latanoprost.
After intracameral dosing in dogs, radioactivity was concentrated in the cornea, iris, ciliary body, and anterior chamber with no radioactivity detected in the eyelids or other periorbital tissues. After topical dosing, radioactivity was distributed in the bulbar conjunctiva, cornea, anterior chamber, iris, ciliary body, upper and lower eyelids, and periorbital tissues (fat/muscle). After intracameral dosing in monkeys, radioactivity was concentrated in the anterior chamber, cornea, iris, ciliary body, and posteriorly along the uveoscleral outflow pathway; there was no radioactivity in the eyelids or periorbital tissues aside from signal in the nasolacrimal duct, likely from reflux of C-latanoprost into the tear film.
Intracameral delivery resulted in more selective target tissue drug exposure. Intracameral drug delivery has potential to reduce ocular surface and periocular adverse effects associated with topical administration of prostaglandin analogues, such as eyelash growth and periorbital fat atrophy.
在比格犬和食蟹猴中,对比单次前房内给药和多次局部眼部给药后,定性评估C-拉坦前列素在眼内及眼周的分布情况。
在犬类研究中,三只动物双侧接受前房内剂量的C-拉坦前列素,并在给药后1、2和4小时实施安乐死;三只对照动物双侧每日一次局部给予C-拉坦前列素,持续5天,并在最后一次给药后1、4和24小时实施安乐死。收集带有周围组织的眼睛矢状面40微米切片并进行放射自显影处理。猴类研究中的方法与之相似;两只动物单侧接受前房内剂量的C-拉坦前列素。
在犬类中进行前房内给药后,放射性集中在角膜、虹膜、睫状体和前房,在眼睑或其他眶周组织中未检测到放射性。局部给药后,放射性分布在球结膜、角膜、前房、虹膜、睫状体、上下眼睑和眶周组织(脂肪/肌肉)中。在猴类中进行前房内给药后,放射性集中在前房、角膜、虹膜、睫状体,并沿葡萄膜巩膜流出途径向后分布;除了鼻泪管中的信号外,眼睑或眶周组织中没有放射性,鼻泪管中的信号可能来自C-拉坦前列素反流到泪膜中。
前房内给药导致更具选择性的靶组织药物暴露。前房内给药有可能减少与局部应用前列腺素类似物相关的眼表和眼周不良反应,如睫毛生长和眶周脂肪萎缩。